TITLE

Back to the drawing-board

PUB. DATE
March 2007
SOURCE
Gut;Mar2007, Vol. 56 Issue 3, p416
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the study focused on the combination use of immunosuppression, selective magnetic resonance imaging (MRI) scanning and examination to rule out Fistulating Crohn's disease. The disease is a therapeutic challenge where treatment agents like infliximab held great promise but infections remains a concern. The study reports outcome of 22 patients with perianal Crohn's disease. Multidisciplinary approach with MRI and infliximab appears to provide safe treatment for the disease.
ACCESSION #
24528574

 

Related Articles

  • Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer, Stephen B. // Gut;Sep2007, Vol. 56 Issue 9, p1181 

    Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

  • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? D'Haens, Geert R.; Panaccione, Remo; Higgins, Peter D. R.; Vermeire, Severine; Gassull, Miquel; Chowers, Yehuda; Hanauer, Stephen B.; Herfarth, Hans; Hommes, Daan W.; Kamm, Michael; Löfberg, Robert; Quary, A.; Sands, Bruce; Sood, A.; Watermayer, G.; Lashner, Bret; Lémann, Marc; Plevy, Scott; Reinisch, Walter; Schreiber, Stefan // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p199 

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability,...

  • Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Albert, J. G.; Martiny, F.; Krummenerl, A.; Stock, K.; Leβke, J.; Göbel, C. M.; Lotterer, E.; Nietsch, H. H.; Behrmann, C.; Fleig, W. E. // Gut;Dec2005, Vol. 54 Issue 12, p1721 

    Background and aims: The diagnostic yield of capsule endoscopy (CE) compared with magnetic resonance imaging (MRI) in small bowel Crohn's disease is not well established. We prospectively investigated CE, MRI, and double contrast Huoroscopy in patients with suspected small bowel Crohn's disease....

  • Ulcerative colitis: value of MR imaging. Maccioni, F.; Colaiacomo, M. C.; Parlanti, S. // Abdominal Imaging;Sep/Oct2005, Vol. 30 Issue 5, p584 

    Recent technologic advances have greatly improved the quality of abdominal magnetic resonance imaging (MRI) by allowing the identification of abnormalities in inflammatory bowel disease. Thus far, the role of MRI has been extensively investigated in Crohn disease (CD) and, to a minor extent, in...

  • A Prospective Comparison Study of MRI versus Small Bowel Follow-Through in Recurrent Crohn's Disease. Bernstein, Charles N.; Greenberg, Howard; Boult, Ian; Chubey, Shirley; Leblanc, Corrine; Ryner, Lawrence // American Journal of Gastroenterology;Nov2005, Vol. 100 Issue 11, p2493 

    BACKGROUND: We aimed to determine the utility of magnetic resonance imaging (MRI) compared with small bowel follow-through (SBFT) in the assessment of known Crohn's disease. METHODS: Subjects, over age 18 yr who were to undergo SBFT investigations to assess for complications or extent of Crohn's...

  • Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Rutgeerts, Paul; Vermeire, Severine; Van Assche, Gert // Gut;Apr2007, Vol. 56 Issue 4, p453 

    The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that...

  • How do patients with inflammatory bowel disease want their biological therapy administered? Allen, Patrick B.; Lindsay, Hannah; Tham, Tony C. K. // BMC Gastroenterology;2010, Vol. 10, p1 

    Background: Infliximab is usually administered by two monthly intravenous (iv) infusions, therefore requiring visits to hospital. Adalimumab is administered by self subcutaneous (sc) injections every other week. Both of these anti-TNF drugs appear to be equally efficacious in the treatment of...

  • Leczenie podtrzymujÄ…ce remisjÄ™ w nieswoistych zapaleniach jelit. Neubauer, Katarzyna; Paradowski, Leszek // Gastroenterologia Polska / Gastroenterology;2010, Vol. 17 Issue 2, p129 

    Maintenance therapy in inflammatory bowel disease (IBD) involves 5′-aminosalicylate derivatives, immunosuppressive drugs (azathioprine, 6-mercaptopurine, methotrexate), and biological agents, which are a breakthrough in the therapy of IBD. Among the biological agents currently available in...

  • Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Biancone, L.; Orlando, A.; Kohn, A.; Colombo, E.; Sostegni, R.; Angelucci, E.; Rizzello, F.; Castiglione, F.; Benazzato, I.; Papi, C.; Meucci, G.; Riegler, G.; Petruzziello, C.; Mocciaro, F.; Geremia, A.; Calabrese, E.; Cottone, M.; Pallone, F. // Gut;Feb2006, Vol. 55 Issue 2, p228 

    Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics